Safety of anacetrapib in patients with or at high risk for coronary heart disease
Open accessAbstract
BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. RESULTS: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001)--a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001)--a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. CONCLUSIONS: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In humans, elevated cholesterol levels are a major risk factor for the development of cardiovascular disease.
“in humans, elevated cholesterol levels are a major risk factor for the development of cardiovascular disease (Cannon et al., 2010).”
From Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears (2014) · cites this paper as Cannon et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works
Self-citationIntensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489 · see citing works
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · see citing works
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774 · see citing works
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 494 · see citing works
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 288 · see citing works
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275 · see citing works
Bloomfield, D. M., Carlson, G. L., Sapre, A., Tribble, D. L., McKenney, J. M., Littlejohn, T. W., Sisk, C. M., Mitchel, Y., & Pasternak, R. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.09.022 · Cited by 242 · see citing works
Self-citationYvan‐Charvet, L., Kling, J., Pagler, T. A., Li, H., Hubbard, B. K., Fisher, T., Sparrow, C. P., Taggart, A. K. P., & Tall, A. R. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.207142 · Cited by 238 · see citing works
Stroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209 · see citing works
Yvan‐Charvet, L., Matsuura, F., Wang, N., Bamberger, M. J., Nguyen, T. T., Rinninger, F., Jiang, X., Shear, C. L., & Tall, A. R. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.106.138347 · Cited by 200 · see citing works
Vasan, R. S., Pencina, M. J., Robins, S. J., Zachariah, J. P. V., Jasuja, G. K., D’Agostino, R. B., & Ordovás, J. M. (2009) · Circulation · doi:10.1161/circulationaha.109.872705 · Cited by 130 · see citing works
Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
Stein, E. A., Roth, E. M., Rhyne, J. M., Burgess, T., Kallend, D. G., & Robinson, J. G. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp601 · Cited by 109 · see citing works
Cannon, C. P., Dansky, H. M., Davidson, M. H., Gotto, A. M., Brinton, E. A., Gould, A. L., Stepanavage, M. E., Liu, S. X., Shah, S., Rubino, J., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.07.028 · Cited by 90 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010 · see citing works
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669 · see citing works
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · see citing works
Self-citationHerrington, W. G., Lacey, B., Sherliker, P., Armitage, J., & Lewington, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.307611 · Cited by 1,483 · see citing works
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227 · see citing works
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047 · see citing works
A Tale of Coronary Artery Disease and Myocardial Infarction
Nabel, E. G., & Braunwald, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112570 · Cited by 994 · see citing works
Grundy, S. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.10.004 · Cited by 882 · see citing works
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870 · see citing works
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822 · see citing works
Self-citationRayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · see citing works
Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality
Evans, D. M., & Smith, G. D. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-050016 · Cited by 524 · see citing works
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521 · see citing works
Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 519 · see citing works
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461 · see citing works
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 456 · see citing works
Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears
Liu, S., Lorenzen, E. D., Fumagalli, M., Li, B., Harris, K., Xiong, Z., Zhou, L., Korneliussen, T. S., Somel, M., Babbitt, C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.054 · Cited by 411 · see citing works
Self-citationNicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410 · see citing works
Selecting instruments for Mendelian randomization in the wake of genome-wide association studies.
Swerdlow, D. I., Kuchenbaecker, K. B., Shah, S., Sofat, R., Holmes, M. V., White, J., Mindell, J. S., Kivimaki, M., Brunner, E. J., Whittaker, J. C., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw088 · Cited by 387 · see citing works
Self-citationHDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354 · see citing works
Ko, D. T., Alter, D. A., Guo, H., Koh, M., Lau, G., Austin, P. C., Booth, G. L., Hogg, W. E., Jackevicius, C. A., Lee, D. S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.038 · Cited by 340 · see citing works
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336 · see citing works
Self-citationOkamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 317 · see citing works
The emerging role of HDL in glucose metabolism
Drew, B. G., Rye, K.-A., Duffy, S. J., Barter, P., & Kingwell, B. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.235 · Cited by 307 · see citing works
Self-citationWadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306 · see citing works
Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA · doi:10.1001/jama.2017.11467 · Cited by 304 · see citing works
Trials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2017) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 303 · see citing works
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 296 · see citing works
Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 292 · see citing works
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 275 · see citing works
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O’Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 258 · see citing works
Self-citationKONES, R. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 257 · see citing works
A Bivariate Genome-Wide Approach to Metabolic Syndrome
Kraja, A. T., Vaidya, D. M., Pankow, J. S., Goodarzi, M. O., Assimes, T. L., Kullo, I. J., Sovio, U., Mathias, R. A., Sun, Y. V., Franceschini, N., et al. (2011) · Diabetes · doi:10.2337/db10-1011 · Cited by 255 · see citing works
Varbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251 · see citing works
HEART UK consensus statement on Lipoprotein(a): A call to action
Cegla, J., Neely, R. D. G., France, M. W., Ferns, G. A., Byrne, C. D., Halcox, J., Datta, D. B. N., Capps, N. E., Shoulders, C. C., Qureshi, N., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.011 · Cited by 248 · see citing works
Melt extrusion with poorly soluble drugs
Shah, S. P., Maddineni, S., Lu, J., & Repka, M. A. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.11.001 · Cited by 243 · see citing works
Self-citationBesler, C., Lüscher, T. F., & Landmesser, U. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200224 · Cited by 219 · see citing works
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
O’Donoghue, M. L., Morrow, D. A., Tsimikas, S., Sloan, S., Ren, A. F., Hoffman, E. B., Desai, N. R., Solomon, S. D., DOMANSKI, M. J., Arai, K., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.042 · Cited by 218 · see citing works
Self-citationFrom Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217 · see citing works
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212 · see citing works
Lüscher, T. F., Taddei, S., Kaski, J. C., Jukema, J. W., Kallend, D. G., Münzel, T. F., Kastelein, J. J. P., & Deanfield, J. E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs019 · Cited by 212 · see citing works
Mendelian randomization studies in coronary artery disease
Jansen, H., Samani, N. J., & Schunkert, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu208 · Cited by 210 · see citing works
Gaudet, D., Kereiakes, D. J., McKenney, J. M., Roth, E. M., Hanotin, C., Gipe, D. A., Du, Y. E., Ferrand, A.-C., Ginsberg, H. N., & Stein, E. A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.05.060 · Cited by 210 · see citing works
Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
Otocka-Kmiecik, A., Mikhailidis, D. P., Nicholls, S. J., Davidson, M. H., Rysz, J., & Banach, M. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.03.003 · Cited by 205 · see citing works
Self-citationBarter, P. J., Rye, K., Tardif, J., Waters, D. D., Boekholdt, S. M., Breazna, A., & Kastelein, J. J. P. (2011) · Circulation · doi:10.1161/circulationaha.111.018259 · Cited by 198 · see citing works
Self-citationMancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., & Pope, J. E. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 184 · see citing works
Desai, N. R., Kohli, P., Giugliano, R. P., O’Donoghue, M. L., Somaratne, R. M., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001969 · Cited by 179 · see citing works
Lipoprotein(a) metabolism: Potential sites for therapeutic targets
Hoover-Plow, J. L., & Huang, M. (2012) · Metabolism · doi:10.1016/j.metabol.2012.07.024 · Cited by 175 · see citing works
High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events
Jia, C., Anderson, J. L. C., Gruppen, E. G., Yu, L., Bakker, S. J. L., Dullaart, R. P. F., & Tietge, U. J. F. (2021) · Circulation · doi:10.1161/circulationaha.120.050808 · Cited by 175 · see citing works
HDL dysfunction in diabetes: causes and possible treatments
Farbstein, D., & Levy, A. P. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.182 · Cited by 174 · see citing works
Residual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J., Davignon, J., Hermans, M. P., Al-Rubeaan, K. A., Amarenco, P., Assmann, G., Barter, P. J., Betteridge, J. D., Bruckert, É., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 173 · see citing works
Self-citationvan Dijk, R. A., Kolodgie, F. D., Ravandi, A., Leibundgut, G., Hu, P., Prasad, A., Mahmud, E., Dennis, E. A., Curtiss, L. K., Witztum, J. L., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p030890 · Cited by 169 · see citing works
High-Density Lipoprotein and Atherosclerosis Regression
Feig, J. E., Hewing, B., Smith, J. D., Hazen, S. L., & Fisher, E. A. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.300760 · Cited by 169 · see citing works
Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists
Fitridge, R., & Thompson, M. M. (2011) · Cited by 168 · see citing works
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 166 · see citing works
Jawi, M., Frohlich, J. J., & Chan, S. (2020) · Journal of Lipids · doi:10.1155/2020/3491764 · Cited by 164 · see citing works
The role of lipoprotein (a) in chronic kidney disease
Hopewell, J. C., Haynes, R., & Baigent, C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083626 · Cited by 157 · see citing works
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156 · see citing works
Soran, H., Hama, S., Yadav, R., & Durrington, P. N. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328355ca25 · Cited by 150 · see citing works
Novel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149 · see citing works
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60312-2 · Cited by 148 · see citing works
Hirata, A., Sugiyama, D., Watanabe, M., Tamakoshi, A., Iso, H., Kotani, K., Kiyama, M., Yamada, M., Ishikawa, S., Murakami, Y., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.014 · Cited by 148 · see citing works
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Barter, P. J., & Rye, K.-A. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024075 · Cited by 145 · see citing works
Self-citationNew insights into the mechanism of low high-density lipoprotein cholesterol in obesity
Wang, H., & Peng, D.-Q. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-176 · Cited by 140 · see citing works
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140 · see citing works
High-density lipoprotein subclasses and their relationship to cardiovascular disease
Superko, H. R., PENDYALA, L. K., Williams, P. T., Momary, K. M., King, S. B., & Garrett, B. C. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.03.001 · Cited by 139 · see citing works
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 133 · see citing works
Novel anti-inflammatory therapies for the treatment of atherosclerosis
Khan, R., Spagnoli, V., Tardif, J., & L’Allier, P. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.783 · Cited by 128 · see citing works
Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy
Morton, J., Zoungas, S., Li, Q., Patel, A. A., Chalmers, J. P., Woodward, M., Celermajer, D. S., Beulens, J. W. J., Stolk, R. P., Glasziou, P., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0306 · Cited by 127 · see citing works
Ballantyne, C. M., McKenney, J. M., MacDougall, D. E., Margulies, J. R., Robinson, P. L., Hanselman, J. C., & Lalwani, N. D. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.043 · Cited by 117 · see citing works
Cao, G., Beyer, T. P., Zhang, Y., Schmidt, R. J., Chen, Y., Cockerham, S. L., Zimmerman, K. M., Karathanasis, S. K., Cannady, E. A., Fields, T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m018069 · Cited by 115 · see citing works
Yeang, C., Hung, M., Byun, Y. S., Clopton, P., Yang, X., Witztum, J. L., & Tsimikas, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.01.005 · Cited by 110 · see citing works
The Changing Face of HDL and the Best Way to Measure It
Karathanasis, S. K., Freeman, L. A., Gordon, S. M., & Remaley, A. T. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.257725 · Cited by 109 · see citing works
Lipoprotein(a): more interesting than ever after 50 years
Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835111d8 · Cited by 105 · see citing works
Cholesteryl ester transfer protein and its inhibitors
Shrestha, S., Wu, B. J., Guiney, L., Barter, P. J., & Rye, K. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082735 · Cited by 104 · see citing works
Self-citationLipoprotein(a), Cardiovascular Disease, and Contemporary Management
Jacobson, T. A. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.09.003 · Cited by 103 · see citing works
Kastelein, J. J. P., Besseling, J., Shah, S., Bergeron, J., Langslet, G., Hovingh, G. K., Al‐Saady, N., Koeijvoets, M., Hunter, J. A., Johnson‐Levonas, A. O., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62115-2 · Cited by 101 · see citing works
Self-citationNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99 · see citing works
Can LDL cholesterol be too low? Possible risks of extremely low levels
OLSSON, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo-Mı́nguez, Á., Cohen, J. C., von Eckardstein, A., Farinaro, E., Müller‐Wieland, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12614 · Cited by 99 · see citing works
Nurmohamed, N. S., Ditmarsch, M., & Kastelein, J. J. P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab350 · Cited by 99 · see citing works
Thomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y., Jumes, P., Wagner, J. A., Hubbard, B., Previs, S. F., et al. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309549 · Cited by 96 · see citing works
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 96 · see citing works
Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
Enkhmaa, B., Petersen, K. H., Kris‐Etherton, P. M., & Berglund, L. (2020) · Nutrients · doi:10.3390/nu12072024 · Cited by 96 · see citing works
Beginning to Understand High-Density Lipoproteins
Santos‐Gallego, C. G., Badimon, J. J., & Rosenson, R. S. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.001 · Cited by 95 · see citing works
Puntoni, M., Sbrana, F., Bigazzi, F., & Sampietro, T. (2012) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03261839 · Cited by 95 · see citing works
Annema, W., & von Eckardstein, A. (2016) · Translational Research · doi:10.1016/j.trsl.2016.02.008 · Cited by 94 · see citing works
The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular Disease
Brewer, H. B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0163 · Cited by 94 · see citing works
Nicholls, S. J., Lincoff, A. M., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Grainger, C., Menon, V., Montalescot, G., Rader, D. J., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.09.007 · Cited by 94 · see citing works
Self-citationImpact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93 · see citing works
Krauss, R. M., Wojnooski, K., Orr, J., Geaney, J. C., Pinto, C. A., Liu, Y., Wagner, J. A., Luk, J. A. M., Johnson‐Levonas, A. O., Anderson, M. S., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m018010 · Cited by 93 · see citing works
Self-citationLipoprotein(a) and Cardiovascular Diseases ― Revisited ―
Jang, A. Y., Han, S. H., Sohn, I. S., Oh, P. C., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0051 · Cited by 93 · see citing works
Nicholls, S. J., Gordon, A., Johannson, J., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Wong, N. C. W., Borgman, M., & Nissen, S. E. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6373-5 · Cited by 92 · see citing works
Self-citationLipoprotein(a): A missing culprit in the management of athero‐thrombosis?
Ferretti, G., Bacchetti, T., Johnston, T. P., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26050 · Cited by 92 · see citing works
Management of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 91 · see citing works
Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters
Maniruzzaman, M., & Nokhodchi, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.007 · Cited by 91 · see citing works
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89 · see citing works
Afshar, M. S., Pilote, L., Dufresne, L., Engert, J. C., & Thanassoulis, G. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003012 · Cited by 89 · see citing works
KONES, R. J. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37119 · Cited by 89 · see citing works
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis
Yeang, C., Wilkinson, M. J., & Tsimikas, S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000300 · Cited by 89 · see citing works
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Millar, J. S., Reyes‐Soffer, G., Jumes, P. A., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., Rafeek, H., Pollan, L. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80025 · Cited by 88 · see citing works
- Authors
- Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., & Barter, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Radiant Research (United States) (US)
- University of Utah (US)
- The Heart Research Institute (AU)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-16
- Volume
- 363
- Issue
- 25
- Pages
- 2406-2415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2090464684
- Cited by
- 749
- References
- 17
- Citations by year
- 2026: 13 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 54 · 2016: 68 · 2015: 83 · 2014: 83 · 2013: 92 · 2012: 116
- FWCI
- 107.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- anacetrapib, cholesteryl ester transfer protein inhibitors, coronary artery disease, LDL cholesterol lowering, HDL cholesterol, statin combination therapy, cardiovascular safety, cardiovascular events, drug safety, high-risk patients, lipid-lowering therapy, blood pressure, electrolytes, aldosterone, Bayesian hierarchical model, cardiovascular hospitalization
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Bayes Theorem, Combined Modality Therapy, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Oxazolidinones, Cholesterol Ester Transfer Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
